Elevated visfatin levels in obese children are related to proinflammatory factors

Journal of Pediatric Endocrinology and Metabolism

Volumn 26, Issue 1-2, 2013, Pages 111-118

  Li, Rui Zhen ^b   Ma, Xin Yu ^b   Hu, Xiu Fen ^a   Kang, Si Xiu ^b   Chen, Shou Kang ^b   Cianflone, Katherine ^c   Lu, Hui Ling ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

Children; Inflammation; Insulin resistance; Obesity; Visfatin

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ANTHROPOMETRIC PARAMETERS; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CHILD; CHILDHOOD OBESITY; CHINESE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MALE; METABOLIC PARAMETERS; SCHOOL CHILD; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADOLESCENT; BODY WEIGHTS AND MEASURES; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHILD; CYTOKINES; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; MALE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OBESITY; OSMOLAR CONCENTRATION; UP-REGULATION;

EID: 84878322290     PISSN: 0334018X     EISSN: 21910251     Source Type: Journal    
DOI: 10.1515/jpem-2012-0237     Document Type: Article

References (43)

1. Aggoun Y. Obesity, metabolic syndrome, and cardiovascular disease. Pediatr Res 2007;61:653-9. (Pubitemid 46804930)
2. Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol 2010;25:129-39.
3. Xu H, Barnes GT, Yang Q, Tan G, Yang D, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112:1821-30. (Pubitemid 38063705)
4. De Heredia FP, Gómez-Martínez S, Marcos A. Obesity, inflammation and the immune system. Proc Nutr Soc 2012;71:332-8.
5. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005;307:426-30. (Pubitemid 40139988)
6. Samal B, Sun Y, Stearns G, Xie C, Suggs S, et al. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994;14:1431-7.
7. Korner A, Garten A, Blüher M, Tauscher R, Kratzsch J, et al. Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab 2007;92:4783-91. (Pubitemid 350223461)
8. Sommer G, Garten A, Petzold S, Beck-Sickinger AG, Bluher M, et al. Visfatin/PBEF/Nampt: structure, regulation and potential function of a novel adipokine. Clin Sci (Lond) 2008;115:13-23. (Pubitemid 351930789)
9. Curat CA, Wegner V, Sengenes C, Miranville A, Tonus C, et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006;49:744- 7. (Pubitemid 43357549)
10. Otero M, Lago R, Gomez R, Lago F, Dieguez C, et al. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:1198-201. (Pubitemid 44277396)
11. Moschen AR, Geiger S, Gerner R, Tilg H. Pre-B cell colony enhancing factor/NAMPT/visfatin and its role in inflammationrelated bone disease. Mutat Res 2010;690:95-101.
12. Liu SW, Qiao SB, Yuan JS, Liu DQ. Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin Endocrinol (Oxf) 2009;71:202-7.
13. Luk T, Malam Z, Marshall JC. Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. J Leukoc Biol 2008;83:804-16. (Pubitemid 351959859)
14. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, et al. Visfatin: an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007;178:1748-58. (Pubitemid 46154646)
15. Fan Y, Meng S, Wang Y, Cao J, Wang C. Visfatin/PBEF/Nampt induces EMMPRIN and MMP-9 production in macrophages via the NAMPT-MAPK (p38, ERK1/2)-NF- κ B signaling pathway. Int J Mol Med 2011;27:607-15.
16. Group of China Obesity Task. Body mass index reference norm for screening overweight and obesity in Chinese children and adolescents. Chin J Epidemiol 2004;25:97-102.
17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9. (Pubitemid 15018832)
19. Dedoussis GV, Kapiri A, Samara A, Dimitriadis D, Lambert D, et al. Visfatin: the link between inflammation and childhood obesity. Diabetes Care 2009;32:e71.
20. Araki S, Dobashi K, Kubo K, Kawagoe R, Yamamoto Y, et al. Plasma visfatin concentration as a surrogate marker for visceral fat accumulation in obese children. Obesity (Silver Spring) 2008;16:384-8. (Pubitemid 351271920)
21. Krzystek-Korpacka M, Patryn E, Bednarz-Misa I, Hotowy K, Noczynska A. Visfatin in juvenile obesity-the effect of obesity intervention and sex. Eur J Clin Invest 2011;41: 1284-91.
22. Taşkesen D, Kirel B, Us T. Serum visfatin levels, adiposity and glucose metabolism in obese adolescents. J Clin Res Pediatr Endocrinol 2012;4:75- 9.
23. Steene-Johannessen J, Kolle E, Reseland JE, Anderssen SA, Andersen LB. Waist circumference is related to low-grade inflammation in youth. Int J Pediatr Obes 2010;5:313-9.
24. Esteghamati A, Morteza A, Zandieh A, Jafari S, Rezaee M, et al. The value of visfatin in the prediction of metabolic syndrome: a multi-factorial analysis. J Cardiovasc Transl Res 2012;5:541-6.
25. Akbal E, Koçak E, TaşA, Y üksel E, KöklüS. Visfatin levels in non-alcoholic fatty liver disease. Clin Lab Anal 2012;26:115-9.
26. Terra X, Auguet T, Quesada I, Aguilar C, Luna AM, et al. Increased levels and adipose tissue expression of visfatin in morbidly obese women. The relationship with pro-inflammatory cytokines. Clin Endocrinol (Oxf) 2011;77:691-8.
27. Dikmen E, Tarkun I, Cantürk Z, Cet i narslan B. Plasma visfatin level in women with polycystic ovary syndrome. Gynecol Endocrinol 2011;27:475- 9.
28. Haus JM, Solomon TP, Marchetti CM, O'Leary VB, Brooks LM, et al. Decreased visfatin after exercise training correlates with improved glucose tolerance. Med Sci Sports Exerc 2009;41:1255-60.
29. Olszanecka-Glinianowicz M, Kocełak P, Nylec M, Chudek J, Zahorska-Markiewicz B. Circulating visfatin level and visfatin/ insulin ratio in obese women with metabolic syndrome. Arch Med Sci 2012;8:214-8.
30. Kolsgaard ML, Wangensteen T, Brunborg C, Joner G, Holven KB, et al. Elevated visfatin levels in overweight and obese children and adolescents with metabolic syndrome. Scand J Clin Lab Invest 2009;69:858-64.
31. Taşçilar ME, Cekmez F, Meral C, Pirgon O, Tanju IA, et al. Evaluation of adipocytokines in obese children with insulin resistance. Turk J Pediatr 2011;53:269-73.
32. Shaker O, El-Shehaby A, Zakaria A, Mostafa N, Talaat S, et al. Plasma visfatin and retinol binding protein-4 levels in patients with type 2 diabetes mellitus and their relationship to adiposity and fatty liver. Clin Biochem 2011;44:1457-63.
33. Wärnberg J, Marcos A. Low-grade inflammation and the metabolic syndrome in children and adolescents. Curr Opin Lipidol 2008;19:11- 5.
34. Galcheva SV, Iotova VM, Yotov YT, Bernasconi S, Street ME. Circulating proinflammatory peptides related to abdominal adiposity and cardiometabolic risk factors in healthy prepubertal children. Eur J Endocrinol 2011;164:553-8.
35. Lee WJ, Wu CS, Lin H, Lee IT, Wu CM, et al. Visfatin-induced expression of inflammatory mediators in human endothelial cells through the NF-kappaB pathway. Int J Obes (Lond) 2009;33:465-72.
36. Liu SW, Qiao SB, Yuan JS, Liu DQ. Visfatin stimulates production of monocyte chemotactic protein-1 and interleukin-6 in human vein umbilical endothelial cells. Horm Metab Res 2009;41:281-6.
37. Tzanavari T, Giannogonas P, Karalis KP. TNF-alpha and obesity. Curr Dir Autoimmun 2010;11:145-56.
38. Gil-Campos M, Ramírez Tortosa MC, Aguilera CM, Ca ñete R, Gil A. Fasting and postprandial adiponectin alterations anticipate NEFA and TNF- α change in prepubertal obese children. Nutr Metab Cardiovasc Dis 2011;21:62-8.
39. Caballero AE, Bousquet-Santos K, Robles-Osorio L, Montagnani V, Soodini G, et al. Overweight Latino children and adolescents have markedendothelial dysfunction and subclinical vascular inflammation in association with excess body fat and insulin resistance. Diabetes Care 2008;31:576-82.
40. Aygun AD, Gungor S, Ustundag B, Gurgoze MK, Sen Y. Proinflammatory cytokines and leptin are increased in serum of prepubertal obese children. Mediat Inflamm 2005;3:180-3. (Pubitemid 41381528)
41. Breslin WL, Johnston CA, Strohacker K, Carpenter KC, Davidson TR, et al. Obese Mexican American children have elevated MCP-1, TNF- α, monocyte concentration, and dyslipidemia. Pediatrics 2012;129:e1180- 6.
42. Huang H, He J, Yuan Y, Aoyagi E, Takenaka H, et al. Opposing effects of estradiol and progesterone on the oxidative stressinduced production of chemokine and proinflammatory cytokines in murine peritoneal macrophages. J Med Invest 2008;55:133-41. (Pubitemid 351643604)
43. Kireev RA, Tresguerres AC, Garcia C, Borras C, Ariznavarreta C, et al. Hormonal regulation of pro-inflammatory and lipid peroxidation processes in liver of old ovariectomized female rats. Biogerontology 2010;11:229-43.